论文部分内容阅读
目的:分析替比夫治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法:考察53例替比夫定治疗HBeAg阳性慢性乙型病毒性肝炎患者的临床表现、生化学、病毒学和病毒基因耐药情况。结果:HBV DNA不可测率、ALT复常率、HBeAg消失率、HBeAg血清转换率和基因型耐药率分别为66.0%、83.7%、73.6%、13.2%和9.4%。结论:替比夫治疗HBeAg阳性慢性乙型肝炎具有良好的临床疗效。
Objective: To analyze the clinical efficacy of telbivill in the treatment of HBeAg-positive chronic hepatitis B patients. Methods: To investigate the clinical manifestations, biochemistry, virology and viral resistance of 53 cases of telbivudine in patients with HBeAg-positive chronic hepatitis B virus. Results: Undetectable HBV DNA, ALT normalization rate, HBeAg disappearance rate, HBeAg seroconversion rate and genotypic drug resistance were 66.0%, 83.7%, 73.6%, 13.2% and 9.4% respectively. Conclusion: Trebeb treatment of HBeAg-positive chronic hepatitis B has good clinical efficacy.